Table 4.
Subgroup | Warfarin cost (£) | Warfarin QALYs | Dabigatran 150 mg bid cost (£) | Dabigatran 150 mg bid QALYs | ICER (£/QALY) | Probability of cost effectiveness* | |
---|---|---|---|---|---|---|---|
At £20 000 per QALY | At £30 000 per QALY | ||||||
RE-LY population | 6480 | 6.390 | 9850 | 6.536 | 23 082 | 0.449 | 0.596 |
CHADS2 score 2 | 7412 | 6.283 | 10 443 | 6.433 | 20 207 | 0.475 | 0.615 |
CHADS2 score ≥3 | 9912 | 6.224 | 12 646 | 6.396 | 15 895 | 0.565 | 0.683 |
Centres’ time in therapeutic range ≥65.5% | 6247 | 6.517 | 9977 | 6.605 | 42 386 | 0.137 | 0.309 |
Centres’ time in therapeutic range <65.5% | 6617 | 6.261 | 9656 | 6.410 | 20 396 | 0.469 | 0.636 |
Patients’ time in therapeutic range ≥66.8% | 6302 | 6.401 | 9850 | 6.536 | 26 281 | 0.393 | 0.511 |
Patients’ time in therapeutic range <66.8% | 6694 | 6.360 | 9850 | 6.536 | 17 932 | 0.519 | 0.643 |
Creatinine clearance <30-50 mL/min | 7991 | 6.310 | 10 788 | 6.460 | 18 647 | 0.501 | 0.631 |
Previous stroke or transient ischaemic attack | 10 004 | 6.217 | 12 787 | 6.378 | 17 286 | 0.525 | 0.649 |
Vitamin K antagonist naive | 6437 | 6.396 | 9792 | 6.545 | 22 517 | 0.446 | 0.587 |
Age ≥75 years | 4612 | 4.275 | 7362 | 4.429 | 17 857 | 0.498 | 0.635 |
bid=twice daily; CHADS2=Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, previous Stroke/transient ischaemic attack; ICER=incremental cost effectiveness ratio; QALY=quality adjusted life year; RE-LY=Randomized Evaluation of Long-Term Anticoagulation Therapy.
*Proportion of simulations in which dabigatran 150 mg twice daily is cost effective versus warfarin.